MARKET

EIGR

EIGR

Eiger Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.75
-0.01
-0.15%
Opening 12:17 05/24 EDT
OPEN
6.66
PREV CLOSE
6.76
HIGH
6.80
LOW
6.43
VOLUME
70.09K
TURNOVER
292.58K
52 WEEK HIGH
10.02
52 WEEK LOW
3.530
MARKET CAP
291.71M
P/E (TTM)
-2.6977
1D
5D
1M
3M
1Y
5Y
EMA's Advisory Committee Recommends Eiger's Zokinvy In Premature Aging Disorder
Benzinga · 3d ago
EU drug regulator panel recommends approval for Eiger BioPharma's progeria therapy
Eiger BioPharmaceuticals (NASDAQ:EIGR) on Friday said that a European Union drug regulator committee had recommended approval of the company's therapy Zokinvy as the first treatment in the region for premature
Seekingalpha · 4d ago
BRIEF-Eiger Receives Positive CHMP Opinion For Zokinvy As A Treatment For Hutchinson-Gilford Progeria Syndrome And Processing-Deficient Progeroid Laminopathies
reuters.com · 4d ago
Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus and other serious diseases, announced today that the Committee for Medicin...
PR Newswire · 4d ago
Eiger BioPharmaceuticals Receives Positive Opinion for Hutchinson-Gilford Progeria Syndrome Treatment Approval in Europe
MT Newswires · 4d ago
Things Look Grim For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) After Today's Downgrade
The analysts covering Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) delivered a dose of negativity to shareholders...
Simply Wall St. · 05/12 10:25
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/11 13:37
BRIEF-Eiger BioPharmaceuticals And AnGes Enter Partnership For Lonafarnib In Japan
reuters.com · 05/10 21:30
More
No Data
Learn about the latest financial forecast of EIGR. Analyze the recent business situations of Eiger Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

100.00%Strong Buy
0.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average EIGR stock price target is 32.00 with a high estimate of 57.00 and a low estimate of 22.00.
High57.00
Average32.00
Low22.00
Current 6.70
EPS
Actual
Estimate
-0.52-0.39-0.26-0.13
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 126
Institutional Holdings: 34.51M
% Owned: 79.85%
Shares Outstanding: 43.22M
TypeInstitutionsShares
Increased
26
3.40M
New
20
4.92M
Decreased
29
773.27K
Sold Out
11
951.37K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.08%
Pharmaceuticals & Medical Research
-0.04%
Key Executives
Non-Executive Chairman/Independent Director
Thomas Dietz
President/Chief Executive Officer/Director
David Cory
Chief Financial Officer
Sriram Ryali
Executive Vice President
Eldon Mayer
Chief Technology Officer
Christopher Kurtz
Chief Compliance Officer/General Counsel
Erik Atkisson
Other
James Shaffer
Director
David Apelian
Independent Director
Jeffrey Glenn
Independent Director
Evan Loh
Independent Director
Christine Murray
Independent Director
Kimberly Sablich
Independent Director
Amit Sachdev
No Data
No Data
About EIGR
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of drugs for serious diseases. Its lead clinical programs are focused on the development of treatments for Hepatitis Delta Virus (HDV), the severe form of viral hepatitis. Its clinical product candidates include Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). LNF is an orally bioavailable, farnesylation inhibitor in a Phase III clinical trial for HDV infection. Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing for the treatment for PBH. Avexitide is for the treatment of congenital hyperinsulinism (CHI), pediatric metabolic disorder.

Webull offers kinds of Eiger Biopharmaceuticals Inc stock information, including NASDAQ:EIGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIGR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EIGR stock methods without spending real money on the virtual paper trading platform.